Demographic characteristics, risk factors and overall cancer prevalence in different clusters of DMT.

<p>SEM: Standard error of the mean. IM: immunomodulatory disease modifying treatments; IS: Immunosuppressant disease modifying treatments.</p

Odds ratio estimates using bootstrap simulations (1000 randomly chosen group of patients based on the propensity score model).

<p>Odds ratio estimates using bootstrap simulations (1000 randomly chosen group of patients based on the propensity score model).</p

Demographic characteristics, risk factors and overall cancer prevalence according to MS disease course.

<p>PP: Primary Progressive; RR: Recurring Remitting; SP: Secondary Progressive; SEM: Standard error of the mean.</p

Overall lifetime cancer prevalence and specific subtypes of cancer prevalence in patients with MS (n = 1107) and controls (n = 1568).

<p>Overall lifetime cancer prevalence and specific subtypes of cancer prevalence in patients with MS (n = 1107) and controls (n = 1568).</p

Propensity score distribution in MS patients and controls.

<p>Patients and controls were matched using a propensity score with nearest neighbor pair matching without replacement within specified calipers (width of 0.2). 1000 bootstrap simulations were then performed.</p

Disease modifying treatments received for at least 3 months.

<p>IM: immunomodulatory disease modifying treatments; IS: Immunosuppressant disease modifying treatments. The total is above 100% as many patients have received more than one DMT during the time course of their disease.</p

Number of multiple sclerosis (MS) cases obtained from each data source for the year 2004.

<p>Number of multiple sclerosis (MS) cases obtained from each data source for the year 2004.</p

Relative risk using the department with the lowest shares of overlap, Moselle ^a.

<p>Relative risk using the department with the lowest shares of overlap, Moselle <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0167556#t006fn001" target="_blank">^a</a>.</p

Relative risk using the department with the highest shares of overlap, Haute-Garonne^a.

<p>Relative risk using the department with the highest shares of overlap, Haute-Garonne<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0167556#t005fn001" target="_blank">^a</a>.</p

Relative risk of MS for each department compared to the mean prevalence for all departments ^a.

<p>Relative risk of MS for each department compared to the mean prevalence for all departments <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0167556#t004fn001" target="_blank">^a</a>.</p